KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Net Cash Flow: 2009-2024

Historic Net Cash Flow for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $182.9 million.

  • Biomarin Pharmaceutical's Net Cash Flow rose 112.10% to $35.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $575.9 million, marking a year-over-year increase of 630.07%. This contributed to the annual value of $182.9 million for FY2024, which is 524.44% up from last year.
  • According to the latest figures from FY2024, Biomarin Pharmaceutical's Net Cash Flow is $182.9 million, which was up 524.44% from $29.3 million recorded in FY2023.
  • Biomarin Pharmaceutical's Net Cash Flow's 5-year high stood at $212.9 million during FY2020, with a 5-year trough of -$61.8 million in FY2021.
  • Moreover, its 3-year median value for Net Cash Flow was $137.2 million (2022), whereas its average is $116.5 million.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Net Cash Flow tumbled by 129.04% in 2021 and then soared by 524.44% in 2024.
  • Over the past 5 years, Biomarin Pharmaceutical's Net Cash Flow (Yearly) stood at $212.9 million in 2020, then plummeted by 129.04% to -$61.8 million in 2021, then surged by 321.95% to $137.2 million in 2022, then plummeted by 78.66% to $29.3 million in 2023, then surged by 524.44% to $182.9 million in 2024.